登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Science，9月2日，A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-09-15

  • A comparison of four serological assays for detecting anti–SARS-CoV-2 antibodies in human serum samples from different populations

    Ludivine Grzelak1,2,3,*, Sarah Temmam4,*, Cyril Planchais5,*, Caroline Demeret6,7,*, Laura Tondeur8, Christèle H

    See all authors and affiliations

    Science Translational Medicine 02 Sep 2020:

    Vol. 12, Issue 559, eabc3103

    DOI: 10.1126/scitranslmed.abc3103

    Abstract

    It is of paramount importance to evaluate the prevalence of both asymptomatic and symptomatic cases of SARS-CoV-2 infection and their differing antibody response profiles. Here, we performed a pilot study of four serological assays to assess the amounts of anti–SARS-CoV-2 antibodies in serum samples obtained from 491 healthy individuals before the SARS-CoV-2 pandemic, 51 individuals hospitalized with COVID-19, 209 suspected cases of COVID-19 with mild symptoms, and 200 healthy blood donors. We used two ELISA assays that recognized the full-length nucleoprotein (N) or trimeric spike (S) protein ectodomain of SARS-CoV-2. In addition, we developed the S-Flow assay that recognized the S protein expressed at the cell surface using flow cytometry, and the luciferase immunoprecipitation system (LIPS) assay that recognized diverse SARS-CoV-2 antigens including the S1 domain and the carboxyl-terminal domain of N by immunoprecipitation. We obtained similar results with the four serological assays. Differences in sensitivity were attributed to the technique and the antigen used. High anti–SARS-CoV-2 antibody titers were associated with neutralization activity, which was assessed using infectious SARS-CoV-2 or lentiviral-S pseudotype virus. In hospitalized patients with COVID-19, seroconversion and virus neutralization occurred between 5 and 14 days after symptom onset, confirming previous studies. Seropositivity was detected in 32% of mildly symptomatic individuals within 15 days of symptom onset and in 3% of healthy blood donors. The four antibody assays that we used enabled a broad evaluation of SARS-CoV-2 seroprevalence and antibody profiling in different subpopulations within one region.

  • 原文来源：https://stm.sciencemag.org/content/12/559/eabc3103
34浏览量
原文链接
相关报告

  • 《bioRxiv，4月3日，SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation》
    • 来源专题：COVID-19科研动态监测
    • 编译者：xuwenwhlib
    • 发布时间：2020-04-05
    • SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation Qiang Zhang, Huajun Zhang, Kun Huang, Yong Yang, Xianfeng Hui, Jindong Gao, Xinglin He, Chengfei Li, Wenxiao Gong, Yufei Zhang, Cheng Peng, Xiaoxiao Gao, Huanchun Chen, Zhong Zou, Zhengli Shi, Meilin Jin doi: https://doi.org/10.1101/2020.04.01.021196 Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China, and rapidly spread worldwide. Previous studies suggested cat could be a potential susceptible animal of SARS-CoV-2. Here, we investigated the infection of SARS-CoV-2 in cats by detecting specific serum antibodies. A cohort of serum samples were collected from cats in Wuhan, including 102 sampled after COVID-19 outbreak, and 39 prior to the outbreak. 15 of 102 (14.7%) cat sera collected after the outbreak were positive for the receptor binding domain (RBD) of SARS-CoV-2 by indirect enzyme linked immunosorbent assay (ELISA). Among the positive samples, 11 had SARS-CoV-2 neutralizing antibodies with a titer ranging from 1/20 to 1/1080. No serological cross-reactivity was detected between the SARS-CoV-2 and type I or II feline infectious peritonitis virus (FIPV). Our data demonstrates that SARS-CoV-2 has infected cat population in Wuhan during the outbreak. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    44浏览量
    原文链接

  • 《MedRxiv，4月16日，（第2版更新）A serological assay to detect SARS-CoV-2 seroconversion in humans》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-17
    • A serological assay to detect SARS-CoV-2 seroconversion in humans Fatima Amanat, Daniel Stadlbauer, Shirin Strohmeier, Thi Nguyen, Veronika Chromikova, Meagan McMahon, Kaijun Jiang, Guha Asthagiri-Arunkumar, Denise Jurczyszak, Jose Polanco, Maria Bermudez-Gonzalez, Giulio Kleiner, Teresa Aydillo, Lisa Miorin, Daniel Fierer, Luz Amarilis Lugo, Erna Milunka Kojic, Jonathan Stoever, Sean T.H. Liu, Charlotte Cunningham-Rundles, Philip L. Felgner, Daniel Caplivski, Adolfo Garcia-Sastre, Allen Cheng, Katherine Kedzierska, Olli Vapalahti, View ORCID ProfileJussi Hepojoki, Viviana Simon, Florian Krammer, Thomas Moran doi: https://doi.org/10.1101/2020.03.17.20037713 Abstract SARS-Cov-2 (severe acute respiratory disease coronavirus 2), which causes Coronavirus Disease 2019 (COVID19) was first detected in China in late 2019 and has since then caused a global pandemic. While molecular assays to directly detect the viral genetic material are available for the diagnosis of acute infection, we currently lack serological assays suitable to specifically detect SARS-CoV-2 antibodies. Here we describe serological enzyme-linked immunosorbent assays (ELISA) that we developed using recombinant antigens derived from the spike protein of SARS-CoV-2. Using negative control samples representing pre-COVID 19 background immunity in the general adult population as well as samples from COVID19 patients, we demonstrate that these assays are sensitive and specific, allowing for screening and identification of COVID19 seroconverters using human plasma/serum as early as two days post COVID19 symptoms onset. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    9浏览量
    原文链接